Cyclacel Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Bio Green Med Solution, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 18, 2026, to be held via a virtual-only format.
Cyclacel Pharmaceuticals, Inc. has filed a Definitive Proxy Statement with the SEC.
A pharmaceutical company has completed a $3 million private placement of convertible preferred stock and warrants, approved by its majority shareholder, to fund operations and address significant financial uncertainties.
Cyclacel Pharmaceuticals, Inc. has filed an amendment to its definitive proxy statement, correcting its total shares outstanding and outlining proposals for its upcoming 2025 Annual Meeting of Stockholders, including director re-elections and an increase in shares for its equity incentive plan.
Cyclacel Pharmaceuticals, Inc. has announced the approval of a reverse stock split by its majority stockholder and Board of Directors, aiming to increase its share price to meet Nasdaq listing requirements and enhance marketability.
Cyclacel Pharmaceuticals is asking stockholders to approve an amendment to its 2018 Equity Incentive Plan to increase the number of shares available for grant by 4,281,987.
Cyclacel Pharmaceuticals is increasing its authorized common stock from 250,000,000 to 600,000,000 shares and issuing Series E Convertible Preferred Stock after receiving approval from a majority stockholder.
Cyclacel Pharmaceuticals is holding a special meeting to seek stockholder approval for several proposals, including a reverse stock split, increased share authorization, and the issuance of common stock upon conversion of preferred stock.
Cyclacel Pharmaceuticals is holding its annual stockholder meeting on June 21, 2024, and is soliciting votes on the election of directors, ratification of the accounting firm, an amendment to the equity incentive plan, and executive compensation.
Cyclacel Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders virtually on June 21, 2024, to vote on key proposals including the re-election of directors, ratification of the accounting firm, an amendment to the equity incentive plan, and executive compensation.